Journal of Nanomaterials / 2013 / Article / Tab 1

Review Article

Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials

Table 1

Nanomedicines approved by one or more regulatory bodies.


DoxilPEGylated liposome/doxorubicin hydrochlorideOvarian cancerApproved 11/17/1995
Ortho Biotech
(acquired by JNJ)
MyocetNon-PEGylated liposomal doxorubicin nanomedicineMetastatic breast cancerApproved in Europe and Canada, in combination with cyclophosphamideSopherion Therapeutics, LLC in North America and Cephalon, Inc. in Europe
DaunoXomeLipid encapsulation of daunorubicinFirst-line treatment for patients with advanced HIV-associated Kaposi's sarcomaApproved in the USAGalen Ltd.
ThermoDoxHeat-activated liposomal encapsulation of doxorubicinBreast cancer, primary liver cancerReceived Fast Track Designation, approval expected by 2013Celsion
AbraxaneNanoparticulate albumin/paclitaxelVarious cancersApproved 1/7/2005
Rexin-GTargeting protein tagged phospholipid/microRNA-122Sarcoma, osteosarcoma, pancreatic cancer, and other solid tumorFully approved in Philippine
Phase II/III (Fast Track Designation, Orphan Drug Status Acquired) in USA
Epeius Biotechnologies Corp.
OncasparPEGylated asparaginaseAcute lymphoblastic leukemiaApproved 24/06/2006Enzon Pharmaceuticals, Inc.
Resovist Iron oxide nanoparticles coated with carboxydextranLiver/spleen lesion imagingIn 2001, approved for the European marketBayer Schering Pharma AG
FeridexIron oxide nanoparticles coated with dextranLiver/spleen lesion imagingApproved by US-FDA in 1996Berlex Laboratories
EndoremIron oxide nanoparticles coated with dextranLiver/spleen lesion imagingApproved in EuropeGuerbet

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.